BOSTON, Jan. 25 /PRNewswire-FirstCall/ -- Surface Logix Inc. announced today the appointment of Steven Gillis, Ph.D. of ARCH Venture Partners to the Company’s Board of Directors. As a member of the Board, Dr. Gillis will provide strategic advice on the Company’s pipeline of new drugs and guidance on advancing new drugs through the clinical development process.
“I am extremely pleased to welcome Steve to the Surface Logix Board,” said Jim Mahoney, CEO of Surface Logix. “During his extensive career, Steve helped to build some of the most successful and highly regarded companies in this industry. His experience and strategic insights will be invaluable to Surface Logix as we are now advancing our programs towards clinical proof of concept.”
Steven Gillis, Ph.D. joined ARCH in 2005 as a Venture Partner focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. Prior to ARCH, Dr. Gillis founded Corixa Corp. (acquired by GlaxoSmithKline in July 2005), where he served as the company’s Chief Executive Officer since its inception and as its Chairman since 1999.
Dr. Gillis was also a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive Officer of Immunex following its majority purchase by American Cyanamid Company and he remained a member of the Board of Directors until 1997. Immunex was acquired by Amgen Inc. in 2002.
An immunologist by training, Dr. Gillis has over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors. Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The Company is advancing multiple internal programs focused primarily on cardiovascular disease, oncology and metabolic disorders and works with strategic partners to create differentiated new chemical entities. For more information, please visit http://www.surfacelogix.com
Contact: David H. Donabedian, Ph.D. Vice President, Business Development Surface Logix Inc. 617.746.8520 Media: Kari Watson MacDougall Biomedical Communications, Inc. 508.647.0209
Surface Logix Inc.
CONTACT: David H. Donabedian, Ph.D., Vice President, Business Developmentof Surface Logix Inc., +1-617-746-8520; or Media: Kari Watson of MacDougallBiomedical Communications, Inc., +1-508-647-0209
Web site: http://www.surfacelogix.com/
